Answers are grounded in this paper and cite their sources.
A new radiopharmaceutical, 99Tcm-hexamethylpropyleneamine oxime (99Tcm-HM-PAO) is described. This agent displays considerable promise for imaging cerebral blood flow. In studies in rats and one human volunteer, 99Tcm-HM-PAO demonstrates good brain uptake, prolonged retention of activity in the brain, and slow regional redistribution. These properties suggest that this new radiopharmaceutical is ideal for single photon emission tomographic (SPECT) imaging of cerebral blood flow.
No takes yet. Share an insight, caveat, or question.
Holmes et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: